2. Search Result
Search Result
Pathways Recommended: Protein Tyrosine Kinase/RTK
Results for "

Tyrosine kinase-IN-1

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

4

Peptides

3

Natural
Products

5

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100315
    XL 999

    TyrosINe kINase-IN-1

    		 VEGFR PDGFR FGFR Cardiovascular Disease Cancer
    XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC50 values for KDR, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer .
    XL 999
  • HY-156619
    Labuxtinib

    		c-Kit Cancer
    Labuxtinib is c-kit tyrosine kinase inhibitor .
    Labuxtinib
  • HY-W002950
    Erlotinib lactam impurity

    		Drug Intermediate Cancer
    Erlotinib lactam impurity (compound 7a) is a precursor of the tyrosine kinase inhibitor .
    Erlotinib lactam impurity
  • HY-P2547A
    Tyrosine Kinase Peptide 1 acetate

    		Src Others
    Tyrosine Kinase Peptide 1 (acetate) is a control substrate peptide for c-Src assay .
    Tyrosine Kinase Peptide 1 acetate
  • HY-148228
    ROS kinases-IN-1

    		ROS Kinase Cancer
    ROS kinases-IN-1 (pag 98) is a ROS tyrosine kinase inhibitor with IC50 value of 1.22 μM. ROS kinases-IN-1 shows anti-tumor activity .
    ROS kinases-IN-1
  • HY-147612
    Tyrosine kinase-IN-4

    		c-Met/HGFR Cancer
    Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor .
    Tyrosine kinase-IN-4
  • HY-159840
    Fanregratinib

    		FGFR Cancer
    Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor .
    Fanregratinib
  • HY-P2547
    Tyrosine Kinase Peptide 1

    		Src Others
    Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .
    Tyrosine Kinase Peptide 1
  • HY-149895
    Syk-IN-7

    		Syk Cancer
    Syk-IN-7 (compound 17) is an inhibitor of spleen tyrosine kinase (SYK) .
    Syk-IN-7
  • HY-101962
    HNMPA

    		Insulin Receptor Metabolic Disease
    HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities
    HNMPA
  • HY-15656S
    Ceritinib-d7

    LDK378 d7

    		 Isotope-Labeled Compounds Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R Endocrinology Cancer
    Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor .
    Ceritinib-d7
  • HY-W062695
    (R)-Acalabrutinib

    (R)-ACP-196

    		 Btk Cancer
    (R)-Acalabrutinib ((R)-ACP-196) is the enantiomer of Acalabrutinib (HY-17600). (R)-Acalabrutinib is an inhibitor for Bruton’s tyrosine kinase (BTK) .
    (R)-Acalabrutinib
  • HY-103032
    Multi-kinase inhibitor 1

    		PDGFR c-Kit Bcr-Abl Cancer
    Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .
    Multi-kinase inhibitor 1
  • HY-117718
    AG957

    TyrphostIN AG957; NSC 654705

    		 Bcr-Abl Cancer
    AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210 bcr/abl autokinase activity .
    AG957
  • HY-135742
    Lenvatinib N-oxide

    LenvatINib impurity 10

    		 VEGFR Cancer
    Lenvatinib N-Oxide (Lenvatinib impurity 10) is the impurity of Lenvatinib (HY-10981). Lenvatinib (E7080) is an orally active, multi-targeted tyrosine kinase inhibitor .
    Lenvatinib N-oxide
  • HY-10331S
    Regorafenib-d3

    BAY 73-4506-d3

    		 VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib-d3 (BAY 73-4506-d3) is a deuterium labeled Regorafenib (HY-10331). Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor .
    Regorafenib-d3
  • HY-131669
    Dasatinib metabolite M6

    DasatINib carboxylic acid

    		 Drug Metabolite Others Cancer
    Dasatinib metabolite M6 (Dasatinib carboxylic acid) is an oxidative metabolite of Dasatinib (HY-10181). Dasatinib is a potent and orally active dual Bcr-Abl and Src family tyrosine kinase inhibitor .
    Dasatinib metabolite M6
  • HY-P1776
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)

    		Insulin Receptor Metabolic Disease
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)
  • HY-P10569
    Biotin HER-2 substrate peptide

    		EGFR Cancer
    Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a Km value of 60 μm for Her2/neu kinase domain .
    Biotin HER-2 substrate peptide
  • HY-15463S
    Imatinib-d8
    1 Publications Verification

    STI571-d8; CGP-57148B-d8

    		 Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
    Imatinib-d8
  • HY-N12041
    Axl-IN-16

    		TAM Receptor HIF/HIF Prolyl-Hydroxylase Cancer
    Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .
    Axl-IN-16
  • HY-162988
    Myt1-IN-5

    		Wee1 Cancer
    Myt1-IN-5 (compound 4) is a membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of less than 200 nM.
    Myt1-IN-5
  • HY-117718R
    AG957 (Standard)

    		Bcr-Abl Cancer
    AG957 (Standard) is the analytical standard of AG957. This product is intended for research and analytical applications. AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210bcr/abl autokinase activity .
    AG957 (Standard)
  • HY-163490
    PKMYT1-IN-1

    		Wee1 Cancer
    PKMYT1-IN-1 (Compound 1) is an inhibitor for membrane-associated tyrosine and threonine kinase (PKMYT1), with an IC50 of 8.8 nM. PKMYT1-IN-1 inhibits proliferation of tumor cell HCC1569 with IC50 of 42 nM .
    PKMYT1-IN-1
  • HY-125017
    Bozitinib
    1 Publications Verification

    PLB-1001; CBT-101; VebreltINib

    		 c-Met/HGFR Cancer
    Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .
    Bozitinib
  • HY-12768A
    Sotuletinib hydrochloride
    Maximum Cited Publications
    34 Publications Verification

    BLZ945 hydrochloride

    		 c-Fms Cancer
    Sotuletinib (BLZ945) hydrochloride is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs .
    Sotuletinib hydrochloride
  • HY-12768
    Sotuletinib
    Maximum Cited Publications
    34 Publications Verification

    BLZ945

    		 c-Fms Cancer
    Sotuletinib (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs .
    Sotuletinib
  • HY-145817
    (Rac)-lunresertib

    (Rac)-RP-6306

    		 Wee1 Cancer
    (Rac)-lunresertib (compound 181) is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. (Rac)-lunresertib (compound 181) has anticancer effects .
    (Rac)-lunresertib
  • HY-50895G
    Gefitinib

    ZD1839

    		 EGFR Autophagy Apoptosis Cancer
    Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor .
    Gefitinib
  • HY-145817B
    (R)-lunresertib

    (R)-RP-6306

    		 Wee1 Cancer
    (R)-lunresertib is a membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor, with IC50 of 1360 nM. (R)-lunresertib can be used in the study of Myt1-mediated cancers .
    (R)-lunresertib
  • HY-15463S1
    Imatinib-d4

    STI571 d4; CGP-57148B d4

    		 Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib-d4 (STI571-d4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
    Imatinib-d4
  • HY-145666
    Myt1-IN-3

    		Wee1 Cancer
    Myt1-IN-3 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50s of <10 nM (WO2021195782 A1, compound 95) .
    Myt1-IN-3
  • HY-145664
    Myt1-IN-1

    		Wee1 Cancer
    Myt1-IN-1 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. Myt1-IN-1 has anticancer effects (WO2021195782A1; compound 132) .
    Myt1-IN-1
  • HY-145665
    Myt1-IN-2

    		Wee1 Cancer
    Myt1-IN-2 is a potent membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of <10 nM. Myt1-IN-2 has anticancer effects (WO2021195782A1; compound 28) .
    Myt1-IN-2
  • HY-157443
    Myt1-IN-4

    		Wee1 Cancer
    Myt1-IN-4 (21) is an orally active and selective membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor, with an IC50 of 2.6 nM. Myt1-IN-4 (21) possesses antitumor activity .
    Myt1-IN-4
  • HY-N6732
    K-252a
    20+ Cited Publications

    SF2370; Antibiotic K 252a; Antibiotic SF 2370

    		 PKC PKA CaMK Trk Receptor Autophagy Antibiotic Infection Inflammation/Immunology
    K-252a, a staurosporine analog, inhibits protein kinase, with IC50 values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca 2+/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .
    K-252a
  • HY-N12625
    (R)-(+)-O-Demethylbuchenavianine

    		CDK DYRK GSK-3 Cancer
    (R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC50s of 1.1, 0.95, >10, >10 and >10 μM, respectively .
    (R)-(+)-O-Demethylbuchenavianine
  • HY-15728
    Radotinib
    1 Publications Verification

    IY-5511

    		 Bcr-Abl Apoptosis STAT JAK Prion Protein Infection Neurological Disease Cancer
    Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .
    Radotinib
  • HY-10408
    Ki20227
    5 Publications Verification

    		 c-Fms VEGFR c-Kit PDGFR Inflammation/Immunology
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .
    Ki20227
  • HY-E70691
    CLK1 Recombinant Human Active Protein Kinase

    		CDK Cancer
    CLK1 is one of the dual specificity kinases and is the founding member of the 'LAMMER' family of kinases. CLK1 activity is positively regulated by phosphorylation on either tyrosine residues or serine/threonine residues, and is negatively regulated by steric constraints mediated by the N-terminal domain, as well as, by phosphorylation on a subset of serine/threonine residues within the catalytic domain. CLK1 Recombinant Human Active Protein Kinase is a recombinant CLK1 protein that can be used to study CLK1-related functions .
    CLK1 Recombinant Human Active Protein Kinase
  • HY-15728S
    Radotinib-d6

    IY-5511-d6

    		 Isotope-Labeled Compounds Bcr-Abl Apoptosis STAT JAK Prion Protein Infection Neurological Disease Cancer
    Radotinib-d6 is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .
    Radotinib-d6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: